{
  "id": "5c6f6ae37c78d69471000054",
  "type": "yesno",
  "question": "Is Lasmiditan effective for migraine?",
  "ideal_answer": "Yes, Lasmiditan is effective for treatment of migraine. This has been demonstrated in clinical trials.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29488143",
    "http://www.ncbi.nlm.nih.gov/pubmed/29352859",
    "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
    "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
    "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
    "http://www.ncbi.nlm.nih.gov/pubmed/29563831",
    "http://www.ncbi.nlm.nih.gov/pubmed/20855362",
    "http://www.ncbi.nlm.nih.gov/pubmed/28103158",
    "http://www.ncbi.nlm.nih.gov/pubmed/30323656",
    "http://www.ncbi.nlm.nih.gov/pubmed/29098075"
  ],
  "snippets": [
    {
      "text": "Amongst the ditans, lasmiditan: (i) fails to constrict human coronary arteries; and (ii) is effective for the acute treatment of migraine in preliminary Phase III clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29352859",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although ongoing phase III clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29488143",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lasmiditan is considered to be the first member of a new drug category, the neurally acting anti-migraine agent (NAAMA)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29563831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323656",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Lasmiditan, a highly selective 5-HT1F agonist, has completed two Phase III randomized, double blind, placebo-controlled clinical trials, with a third - a long-term, open-label safety study - still underway. Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323656",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0-3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6-3.0, p< 0.001). Furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; OR 1.6, 95% CI 1.3-2.1, p< 0.001) and lasmiditan 100 mg (40.9%; OR 1.7, 95% CI, 1.3-2.2, p< 0.001) were free of their MBS at 2 hours after dosing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT(1F) receptor agonist like lasmiditan is effective in the acute treatment of migraine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While lasmiditan most likely is effective in the treatment of migraine attacks it had, unfortunately, a high incidence of CNS related AEs in the oral RCT. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.At intravenous doses of 20 mg and higher, lasmiditan proved effective in the acute treatment of migraine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20855362",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323656",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND\nLasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nOral lasmiditan seems to be safe and effective in the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 5-HT1F receptor agonist lasmiditan, a drug acting through non-vasoconstrictive mechanisms, represents a promising safe, effective and tolerated acute migraine therapy also for patients at cardiovascular risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28103158",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT(1F) receptor agonist like lasmiditan is effective in the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Within the past few years, new and promising drugs such as more specific 5-HT 1F receptor agonists (that is, lasmiditan) and monoclonal calcitonin gene-related peptide (CGRP) receptor antibodies entered advanced development phases while non-invasive neuromodulatory approaches were suggested to be potentially effective as non-pharmaceutical interventions for migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29098075",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CLASSIFICATION OF EVIDENCE\nThis study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Oral lasmiditan seems to be safe and effective in the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323656",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The non-vascular, neural mechanism of action of lasmiditan may offer an alternative means to treat migraine especially in patients who have contra-indications for agents with vasoconstrictor activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20855362",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0-3.6, <br><b>CONCLUSIONS</b>: Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors.<br><b>CLINICALTRIALSGOV IDENTIFIER</b>: NCT02439320.<br><b>CLASSIFICATION OF EVIDENCE</b>: This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence.<br><b>INTERPRETATION</b>: Oral lasmiditan seems to be safe and effective in the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dizziness, paresthesia and sensations of heaviness (usually limb) were more common on lasmiditan.<br><b>CONCLUSIONS</b>: At intravenous doses of 20 mg and higher, lasmiditan proved effective in the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20855362",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND</b>: Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT(1F) receptor agonist like lasmiditan is effective in the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While lasmiditan most likely is effective in the treatment of migraine attacks it had, unfortunately, a high incidence of CNS related AEs in the oral RCT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430431",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}